News & Updates
Filter by Specialty:
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
Use of low-dose aspirin appears to have a null effect on the 5-year survival of patients who undergo gastrectomy for gastric adenocarcinoma, a study reports.
Low-dose aspirin yields no survival benefit in gastric adenocarcinoma
24 Apr 2022
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
In the treatment of ischemic symptoms associated with peripheral arterial disease, the use of once-daily SID142 appears to be as good as twice-daily Renexin while having a favourable safety profile, as shown in a phase III study.
Once- on par with twice-daily cilostazol–Ginkgo biloba combo in peripheral arterial disease
23 Apr 2022
New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.
New oral tyrosine kinase 2 inhibitor shows promise against moderate-to-severe plaque psoriasis
23 Apr 2022
Circulating antioxidants play no protective role in breast, ovarian cancers
Genetically predicted circulating antioxidants do not appear to have a protective effect on the risk of breast cancer, ovarian cancer, or their histotypes, according to the results of a two-sample Mendelian randomization study.
Circulating antioxidants play no protective role in breast, ovarian cancers
23 Apr 2022
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
Treatment-naïve patients with locally advanced or metastatic EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC) experience improved progression-free survival (PFS) when treated with furmonertinib compared with gefitinib, according to results of the phase III FURLONG study.
Furmonertinib emerges as potential first-line option for EGFRm NSCLC
22 Apr 2022
Ritlecitinib, brepocitinib show promise against scalp alopecia areata
Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.